The role of E2F transcription factors family in Urothelial Carcinoma

Georgia Pantelopoulou¹, Christos Alamanis¹, Ioannis Adamakis¹, Athanasios Kotsinas², Kalliopi Kostelidou^3✉

1. First University Urology Clinic, Laiko Hospital, University of Athens, 17, Ag.Thoma Str, GR11527, Athens, Greece
2. Molecular Carcinogenesis Group, Department of Histology and Embryology, School of Medicine, National Kapodistrian University of Athens, 75 Mikras Asias Str, GR11527, Athens, Greece
3. Bone Marrow Transplant Unit, Haematology-Lymphoma Clinic, Evangelismos General Hospital, 45-47 Ypsilantou Str, GR10676, Athens, Greece

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Citation:
Pantelopoulou G, Alamanis C, Adamakis I, Kotsinas A, Kostelidou K. The role of E2F transcription factors family in Urothelial Carcinoma. Oncomedicine 2018; 3:110-116. doi:10.7150/oncm.22098. Available from http://www.oncm.org/v03p0110.htm

Abstract

E2F transcription factor family is a group of 8 proteins that interact with pocket proteins and bind to target DNA in order to modulate cell cycle progression. Thus, their role is pivotal to cancer development and progression. Bladder cancer, a prominent cancer that affects both sexes, is also affected by E2F. E2F-1, E2F-3 and E2F-4 and -5 have a distinct impact on bladder development, progress and prognosis. However the role of the remaining E2Fs remains obscure, awaiting newer data that could provide useful therapeutic targets.

Keywords: E2F transcription factor, cancer, bladder, apoptosis, regulation